EGFR and colorectal carcinoma: Therefore, the need to identify additional biomarkers—detectable either in tissue or blood—to predict intrinsic or acquired resistance is very urgent, especially in the case of resistance to anti-EGFR drugs, given that they have been the first targeted drugs employed for the treatment of CRC and are so far the most used.